SCM
AVBP icon

Sterling Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Sterling Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.82K Buy
209
+22
+12% +$497 ﹤0.01% 2750
2025
Q4 		$3.76K Buy
187
+127
+212% +$2.64K ﹤0.01% 2966
2025
Q3 		$1.11K Buy
60
+4
+7% +$79 ﹤0.01% 3065
2025
Q2 		$1.22K Sell
56
-153
-73% -$3.18K ﹤0.01% 3030
2025
Q1 		$3.86K Sell
209
-164
-44% -$4.01K ﹤0.01% 2288
2024
Q4 		$9.94K Buy
373
+314
+532% +$9.02K ﹤0.01% 2165
2024
Q3 		$1.39K Buy
+59
New +$1.34K ﹤0.01% 2373

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Sterling Capital Management's AVBP Position: Q1 2026 in Review

Sterling Capital Management increased its ArriVent BioPharma (AVBP) stake by 12% in Q1 2026, buying an estimated $497 and bringing the position to 209 shares worth $4.82K. The position accounts for ﹤0.01% of the portfolio, ranked #2750.

Sterling Capital Management first reported a position in AVBP in Q3 2024 and has held it in 7 quarters since. The position peaked at $9.94K in Q4 2024. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Sterling Capital Management held 209 shares of ArriVent BioPharma worth $4.82K as of Q1 2026.
  • Sterling Capital Management bought 22 ArriVent BioPharma shares in Q1 2026, an estimated $497.
  • ArriVent BioPharma made up ﹤0.01% of Sterling Capital Management's portfolio in Q1 2026, its #2750 holding.
  • Sterling Capital Management first reported a position in ArriVent BioPharma in Q3 2024 and has held it in 7 quarters since.
  • Sterling Capital Management's ArriVent BioPharma position peaked at $9.94K in Q4 2024.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Sterling Capital Management's 13F filing for Q1 2026, filed 22 Apr 2026.